Relay Therapeutics, Inc. Common Stock
Compare this stock
RLAY Stock Report Card
$
25%
Performance
Score:
10/100
RLAY returned -58.37% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Technicals
Score:
64/100
RLAY receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.
Earnings
Score:
10/100
RLAY has missed earnings 8 times in the last 20 quarters.
Profit
Score:
10/100
Out of the last 19 quarters, RLAY has had 1 profitable quarters and has increased their profits year over year on 1 of them.
Volatility
Score:
53/100
RLAY has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.
Relay Therapeutics, Inc. Common Stock Summary
Nasdaq / RLAY
Healthcare
Biotechnology
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
RLAY scored poorly on our reportcard. Here are some similar companies and how they performed.